NasdaqGS - Nasdaq Real Time Price • USD
Agios Pharmaceuticals, Inc. (AGIO)
As of 1:09 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Brian M. Goff M.B.A. | CEO & Director | 1.23M | -- | 1969 |
| Ms. Cecilia Jones | Chief Financial Officer | 403.36k | -- | 1975 |
| Mr. James William Burns | Corporate Secretary & Chief Legal Officer | 660.33k | -- | 1978 |
| Dr. Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of Research & Development | 769.2k | -- | 1980 |
| Dr. Lewis Clayton Cantley Ph.D. | Co-Founder & Member of Scientific Advisory Board | 50k | -- | 1949 |
| Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. | Co-Founder & Member of Scientific Advisory Board | -- | -- | 1946 |
| Dr. Craig B. Thompson M.D. | Co-Founder & Chairman of Scientific Advisory Board | -- | -- | 1953 |
| Dr. Shin-San Su Ph.D. | Co-Founder & Member of Scientific Advisory Board | -- | -- | 1956 |
| Mr. T. J. Washburn Jr. | Principal Accounting Officer | -- | -- | 1981 |
| Dr. Clive Patience Ph.D. | Chief Technical Operations Officer | -- | -- | 1964 |
Agios Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 383
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Agios Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 7; Compensation: 6.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Feb 15, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 25, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Jan 22, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Jan 08, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Nov 02, 20238-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
May 02, 2024
Agios Pharmaceuticals, Inc. Earnings Call
Related Tickers
PTCT PTC Therapeutics, Inc.
25.31
+0.40%
RARE Ultragenyx Pharmaceutical Inc.
43.30
-2.22%
BPMC Blueprint Medicines Corporation
90.87
-1.51%
CGEM Cullinan Therapeutics, Inc.
19.20
+1.64%
PTGX Protagonist Therapeutics, Inc.
24.85
-3.33%
ENTA Enanta Pharmaceuticals, Inc.
12.56
-2.79%
ALNY Alnylam Pharmaceuticals, Inc.
144.28
+0.33%
IONS Ionis Pharmaceuticals, Inc.
42.33
-0.28%
AVTE Aerovate Therapeutics, Inc.
21.10
-0.47%
BMRN BioMarin Pharmaceutical Inc.
82.28
-9.78%